---

---

•	Revenue was $17.5 million, a decline of 6%. Revenue accrued for tests performed in the current year quarter increased 24%, offset by the impact of higher cash collections in the prior year quarter for tests performed prior to July 1, 2016;

•	Genomic Test Volume was 6,533, an increase of 14%;

•	Operating Expenses were $23.9 million, an increase of 2%;

•	Net Loss and Comprehensive Loss was $7.0 million, an increase of 25%;

•	Net Loss Per Common Share was $0.21 compared to $0.20;

•	Cash Burn, defined as net cash used in operating activities and net capital expenditures, was $5.8 million, an improvement of 23%; and

•	Cash and Cash Equivalents was $41.2 million at September 30, 2017.

•	Revenue was $52.4 million, an increase of 12%;

•	Genomic Test Volume was 18,873, an increase of 12%;

•	Operating Expenses were $72.9 million, an increase of 1%;

•	Net Loss and Comprehensive Loss was $22.6 million, an improvement of 16%;

•	Net Loss Per Common Share was $0.67, an improvement of 31% from $0.97; and

•	Cash Burn was $19.1 million, an improvement of 31%.

---

•

In November 2017, the Company closed a $35 million senior secured credit facility, consisting of a $25 million term loan and a $10 million asset-based revolving line of credit to refinance its existing $25 million credit facility, reducing the current variable interest rate by over 50% and providing additional liquidity through a new revolving line of credit. The Company paid a $1.5 million exit fee at the close to its prior lender.

•

In October 2017, the Company amended and restated its Thyroid Cytopathology Partners (TCP) agreement. In return for lower fees, the Company agreed to extend the term for five years and to pay $1.75 million to Pathology Resource Consultants, TCP’s previous management company, over eight quarters. Based on current volumes, the Company believes the amendment will be immediately accretive to earnings as well as cash burn.

•	Gained 100 new accounts for our next-generation Afirma GSC and continued to transition existing accounts.

•	Grew genomic test volume by 14% in the third quarter of 2017, compared to the third quarter of 2016.

•	Generated our first commercial revenue for the Percepta Bronchial Genomic Classifier and expanded its use to over 70 institutions.

•	Launched the Screen Together awareness campaign with the Lung Cancer Initiative of North Carolina to increase lung cancer screening awareness among high-risk people.

•	Increased contracted lives for the Afirma classifier by 13 million through the execution of five new contracts, including four Blues plans. This brings the total number of contracted lives for the test to 176 million and increases from last quarter the number of contracted Blues lives by 35% to 45 million.

•	Received preliminary 2018 Medicare pricing indicating that the Afirma classifier price will increase from $3,220 to $3,600. Pending a public comment period, the final rates are scheduled to begin January 1, 2018, as part of the Protecting Access to Medicare Act of 2014 (PAMA).

•	Presented data from five studies (two oral and three poster presentations) highlighting the Afirma GSC’s advances in informing both benign and cancerous subtypes of thyroid nodules at the 87th Annual Meeting of the American Thyroid Association (ATA).

•	Delivered podium presentation of clinical utility data for the Percepta classifier at the CHEST Annual Meeting. Findings showed that the use of Percepta reduces the number of invasive procedures by 50% in patients whom the test classifies as low-risk for lung cancer following an inconclusive bronchoscopy result.

•	Received acceptance of an abstract demonstrating clinical utility of the Envisia Genomic Classifier in the diagnosis of idiopathic pulmonary fibrosis for presentation at the PFF Summit in November.

---

---

---

---

---